Related Experiment Videos
Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances
Predrag Sikiric1, Nikola Jelovac, Andjelka Jelovac-Gjeldum
1Department of Pharmacology, Medical Faculty University of Zagreb, Salata 11, POB 916, 10000 Zagreb, Croatia. sikiric@mef.hr.
Acta Pharmacologica Sinica
|April 30, 2002
Summary
Pentadecapeptide BPC 157 successfully attenuated chronic amphetamine effects in rats, reducing both tolerance and reverse tolerance. This suggests BPC 157 may modulate the dopamine system and aid in managing amphetamine-induced disturbances.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Chronic amphetamine use leads to tolerance and reverse tolerance, characterized by altered behavioral responses.
- Understanding the neurobiological mechanisms underlying these changes is crucial for developing effective interventions.
Purpose of the Study:
- To investigate the effects of pentadecapeptide BPC 157 on amphetamine-induced tolerance and reverse tolerance in a rat model.
- To determine if BPC 157 can mitigate behavioral changes associated with chronic amphetamine exposure.
Main Methods:
- Rats received daily amphetamine doses, followed by intermittent challenges.
- Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/kg) or saline was administered at the initial amphetamine exposure.
- Stereotyped behavior and startle response were monitored throughout the study.
Main Results:
- BPC 157 significantly attenuated stereotyped behavior and heightened startle response induced by amphetamine.
- The protective effects of BPC 157 persisted throughout the chronic amphetamine administration and subsequent challenges.
- Both higher and lower doses of BPC 157 demonstrated significant modulatory effects.
Conclusions:
- Gastric pentadecapeptide BPC 157 effectively attenuated behavioral disturbances associated with chronic amphetamine exposure in rats.
- BPC 157 demonstrates a modulatory effect on the dopamine system.
- These findings suggest BPC 157's potential therapeutic utility in managing chronic amphetamine disturbances.